Filana Therapeutics, Inc. (FLNA) Income Statement
FLNA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsFLNA revenue and net income
FLNA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
FLNA quarterly EPS vs estimates
Filana Therapeutics beat the analyst EPS estimate in 6 of the last 6 quarters. Next report: November 11, 2026.
FLNA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $936,000 | — | — | — | — |
| Gross profit | −$936,000 | — | — | — | — |
| Research & development | $26.6M | $69.6M | $89.4M | $68.0M | $24.8M |
| Sales, general & admin | $68.8M | $71.8M | $16.5M | $12.0M | $8.1M |
| Total operating expenses | $94.5M | $141.4M | $106.0M | $80.0M | $32.9M |
| Operating income | −$95.4M | −$141.4M | −$106.0M | −$80.0M | −$32.9M |
| Interest income | $4.6M | $8.5M | $7.8M | $2.8M | — |
| Income before taxes | −$91.0M | −$24.3M | −$97.2M | −$76.2M | −$32.4M |
| Net income | −$91.0M | −$24.3M | −$97.2M | −$76.2M | −$32.4M |
| EBITDA | −$90.0M | −$141.1M | −$105.8M | −$80.2M | −$31.9M |
| EPS (diluted) | −$1.88 | −$2.86 | −$2.32 | −$1.90 | −$0.81 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $300,000 | $243,000 | $367,000 | — | — | — | — | — |
| Gross profit | −$300,000 | −$243,000 | −$367,000 | — | — | — | — | — |
| Research & development | $3.3M | $4.5M | $3.9M | $4.0M | $5.1M | $13.7M | $20.5M | $17.7M |
| Sales, general & admin | $6.1M | $6.6M | $9.7M | $7.9M | $40.3M | $10.9M | $9.0M | $12.9M |
| Total operating expenses | $9.1M | $10.9M | $13.2M | $11.9M | $45.4M | $24.6M | $29.5M | $30.6M |
| Operating income | −$9.4M | −$11.2M | −$13.6M | −$11.9M | −$45.4M | −$24.6M | −$29.5M | −$30.6M |
| Interest income | $747,000 | $789,000 | $974,000 | $1.2M | $1.2M | $1.3M | $1.8M | — |
| Income before taxes | −$8.6M | −$10.3M | −$12.5M | −$10.8M | −$44.2M | −$23.4M | −$27.6M | −$27.9M |
| Net income | −$8.6M | −$10.3M | −$12.5M | −$10.8M | −$44.2M | −$23.4M | −$27.6M | −$27.9M |
| EBITDA | −$9.1M | −$10.1M | −$12.2M | −$10.7M | −$44.0M | −$23.2M | −$30.1M | −$27.7M |
| EPS (diluted) | −$0.18 | −$0.21 | −$0.26 | −$0.22 | −$0.92 | −$0.48 | −$0.57 | −$0.58 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in FLNA's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
FLNA financial results
Filana Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $91.0 million. Diluted earnings per share came to −$1.88.
See the FLNA stock overview for the latest quote and news, or the FLNA chart for price history and technical indicators.
FLNA income statement FAQ
Does Filana Therapeutics have revenue?
Filana Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Filana Therapeutics profitable?
No. Filana Therapeutics reported a net loss of $91.0 million in fiscal 2025.
How much does Filana Therapeutics spend on research and development?
Filana Therapeutics spent $26.6 million on research and development in fiscal 2025.
What are Filana Therapeutics's earnings per share?
Filana Therapeutics earned $-1.88 per diluted share in fiscal 2025, compared with $-2.86 a year earlier.
When will Filana Therapeutics report its next earnings?
Filana Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Filana Therapeutics's fiscal year end?
Filana Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.